Dacarbazine
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | DTIC-DOME | — | 1981-04-29 | fda.gov ↗ |
| Approved | US (FDA) | DTIC-DOME | — | 1975-05-27 | fda.gov ↗ |
Trials 136 · started per year
Also used as a comparator or background therapy in 91 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03761095 Background | Mar 2019 → Feb 2024 | leiomyosarcoma | PTC Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01056679 Background | Apr 2010 → Apr 2014 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 1 | NCT01060904 Background | Jan 2010 → Sep 2012 | Hodgkins lymphoma | Seagen Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00796991 Comparator | Feb → Nov 2009 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00498979 Background | May 2007 → May 2010 | melanoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00516802 Background | Jan 2007 → Jan 2009 | melanoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02979522 Background | Sep 2017 → May 2020 overdue | classic Hodgkin lymphoma | Takeda | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03033914 Background | Jan 2017 → Jan 2027 expected | classic Hodgkin lymphoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 237 trials | ||||||
| Phase 2 | NCT07406724 Comparator | Feb 2026 → Dec 2027 expected | melanoma | Qingdao Sino-Cell Biomedicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07400302 Background | Feb 2026 → Sep 2029 expected | mucosal melanoma | The First Hospital of Jilin University | Recruiting | No outcome recorded |
| Phase 2 | NCT07310784 Comparator | Dec 2025 → Dec 2027 expected | melanoma | Suzhou BlueHorse Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06703398 Comparator | Dec 2024 → Jul 2026 overdue | melanoma | Shanghai Juncell Therapeutics | Recruiting | No outcome recorded |
| Phase 2 | NCT05627115 Background | Mar 2024 → Oct 2028 expected | Hodgkins lymphoma | University College, London | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05772624 Background | Feb 2023 → Mar 2024 | — | Hospital Universitario Dr. Jose E. Gonzalez | Unknown | No outcome recorded |
| Phase 2 | NCT05253495 Background | Feb 2022 → Dec 2027 expected | Hodgkins lymphoma, non-Hodgkin lymphoma | New York Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT03407144 Background | Apr 2018 → Nov 2026 expected | classic Hodgkin lymphoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03527628 Background | Jan 2018 → Jan 2021 | classic Hodgkin lymphoma | King Abdullah International Medical Research Center | Unknown | No outcome recorded |
| Phase 2 | NCT03070392 Comparator | Oct 2017 → Oct 2020 | uveal melanoma | Immunocore Ltd | Completed | No outcome recorded |
| Phase 2 | NCT04200040 Comparator | Aug 2017 → Dec 2022 | cutaneous melanoma | OrienGene Biotechnology Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT02505269 Background | Aug 2015 → Jun 2019 | Hodgkins lymphoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02292979 Background | Mar 2015 → Dec 2016 | Hodgkins lymphoma | The Lymphoma Academic Research Organisation | Completed | No outcome recorded |
| Phase 2 | NCT02181738 Background | Aug 2014 → Aug 2017 | Hodgkins lymphoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01920932 Background | Aug 2013 → Nov 2020 overdue | Hodgkins lymphoma | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02275598 Background | Apr → Nov 2013 | Hodgkins lymphoma | University of Modena and Reggio Emilia | Unknown | No outcome recorded |
| Phase 2 | NCT01705392 Comparator | Jan 2013 → Feb 2017 | metastatic melanoma | Haukeland University Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01693068 Comparator | Dec 2012 → Jul 2015 | cutaneous melanoma | EMD Serono | Completed | No outcome recorded |
| Phase 2 | NCT01569204 Comparator | Oct 2012 → Mar 2014 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT01534078 Background | Mar 2012 → Jan 2015 | Hodgkins lymphoma | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00797472 Comparator | Jul 2011 → Apr 2014 | Hodgkins lymphoma | American Scitech International | Unknown | No outcome recorded |
| Phase 2 | NCT01551459 Comparator | Oct 2010 → Sep 2017 | uveal melanoma | The Clatterbridge Cancer Centre NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT01152788 Comparator | Aug 2010 → Nov 2014 | melanoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT01028222 Comparator | Jun 2010 → Dec 2014 | melanoma | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00991250 Comparator | Oct 2009 → Sep 2011 | melanoma | SentoClone AB | Unknown | No outcome recorded |
| Phase 2 | NCT00936221 Comparator | Jul 2009 → Nov 2011 | melanoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00822120 Comparator | Jul 2009 → Apr 2016 | lymphoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT05898451 Background | Jun 2009 → Nov 2011 | cancer | Refnot-Pharm Ltd | Completed | No outcome recorded |
| Phase 2 | NCT00849875 Background | May 2009 → Nov 2014 | melanoma | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT00654732 Background | Mar 2008 → Sep 2018 | classic Hodgkin lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00533702 Comparator | Nov 2007 → May 2011 | metastatic melanoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00308607 Background | Aug 2005 → Dec 2008 | metastatic melanoma | University of Turku | Completed | No outcome recorded |
| Phase 2 | NCT00130442 Comparator | Jun 2005 → Oct 2010 | melanoma | Cellxpert Biotechnology Corp. | Completed | No outcome recorded |
| Phase 2 | NCT00492297 Background | Apr 2005 → Jun 2008 | melanoma | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00110994 Background | Apr 2005 → Oct 2006 | cancer, melanoma | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00911443 Background | Jul 2002 → Sep 2007 | melanoma | sigma-tau i.f.r. S.p.A. | Completed | No outcome recorded |
| Phase 2 | NCT01404936 Background | Jul 1996 → Dec 2011 | lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT06624644 Comparator | Aug 2025 → Feb 2029 expected | cutaneous melanoma | Linnaeus Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05987332 Comparator | Oct 2023 → Jan 2027 expected | uveal melanoma | IDEAYA Biosciences | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05269355 Background | May 2022 → Jun 2024 | leiomyosarcoma | PTC Therapeutics | Terminated | No outcome recorded |
| Phase 337 trials | ||||||
| Phase 3 | NCT06743126 Comparator | Jan 2025 → Jan 2028 expected | cutaneous melanoma | Immatics US, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06264180 Comparator | Jul 2024 → Sep 2030 expected | melanoma | Replimune, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06346067 Comparator | Apr 2024 → Apr 2028 expected | melanoma | Erasca, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06008106 Comparator | Nov 2023 → Sep 2027 expected | melanoma | Shanghai Kechow Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT03907488 Background | Aug 2019 → Mar 2024 overdue | Hodgkin's lymphoma, lymphocytic depletion, Hodgkin's lymphoma, mixed cellularity, nodular sclerosis classical Hodgkin lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03430297 Comparator | Feb 2018 → Jul 2023 | metastatic melanoma | Shanghai Junshi Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02684708 Comparator | Oct 2015 → Oct 2024 | classic Hodgkin lymphoma | University of Giessen | Completed | No outcome recorded |
| Phase 3 | NCT02288897 Comparator | Apr 2015 → Apr 2019 | cutaneous melanoma | Provectus Biopharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT01974752 Background | Apr 2014 → May 2015 | metastatic malignant neoplasm, uveal melanoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02049905 Comparator | Jan 2014 → May 2017 | soft tissue sarcoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01763164 Comparator | Jul 2013 → Dec 2015 | cutaneous melanoma | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01721772 Comparator | Jan 2013 → Jun 2014 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01721746 Comparator | Dec 2012 → Feb 2016 | metastatic melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT01712490 Background | Nov 2012 → Apr 2017 | Hodgkins lymphoma | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01692678 Comparator | Aug 2012 → Oct 2016 | liposarcoma | Xian-Janssen Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01356680 Background | Jan 2012 → Mar 2020 | Hodgkins lymphoma | University of Cologne | Completed | No outcome recorded |
| Phase 3 | NCT00816959 Comparator | Jul 2011 → Apr 2014 | Hodgkins lymphoma | American Scitech International | Unknown | No outcome recorded |
| Phase 3 | NCT01343277 Comparator | Jun 2011 → Jan 2015 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT01327885 Comparator | Mar 2011 → Jan 2015 | soft tissue sarcoma | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01280565 Comparator | Jan 2011 → Aug 2019 | metastatic melanoma | AB Science | Terminated | No outcome recorded |
| Phase 3 | NCT01227889 Comparator | Dec 2010 → Dec 2011 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01006980 Comparator | Jan → Dec 2010 | melanoma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00736320 Background | Nov 2009 → Sep 2018 | Hodgkins lymphoma | University of Cologne | Unknown | No outcome recorded |
| Phase 3 | NCT00864253 Comparator | Apr 2009 → Jun 2012 | melanoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT00779714 Comparator | Oct 2008 → Oct 2012 | melanoma | University of Wuerzburg | Unknown | No outcome recorded |
| Phase 3 | NCT00678327 Comparator | Aug 2008 → Jan 2016 | lymphoma | University College, London | Completed | No outcome recorded |
| Phase 3 | NCT00518895 Background | Jul 2007 → May 2011 | melanoma | Genta Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT00395070 Comparator | Oct 2006 → Mar 2012 | metastatic melanoma | Vical | Completed | No outcome recorded |
| Phase 3 | NCT00324155 Background | Aug 2006 → Jan 2011 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00257205 Comparator | Mar 2006 → Aug 2010 | melanoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00091572 Comparator | Oct 2004 → Dec 2007 | melanoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00087776 Comparator | Dec 2002 → Oct 2007 | melanoma | American Regent, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00049595 Comparator | Aug 2002 → Jan 2010 | lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT01359956 Background | Apr 2002 → Feb 2011 | melanoma | National Cancer Institute, Naples | Completed | No outcome recorded |
| Phase 3 | NCT00038558 Background | Nov 2001 → Feb 2004 | Hodgkins lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT01251107 Comparator | Mar 2000 → Nov 2009 | Hodgkins lymphoma | Fondazione Michelangelo | Completed | No outcome recorded |
| Phase 3 | NCT00002561 Comparator | Jan 1994 → Aug 2011 | Hodgkins lymphoma | NCIC Clinical Trials Group | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06831370 Background | Aug 2024 → Mar 2028 expected | Hodgkins lymphoma | Takeda | Recruiting | No outcome recorded |
| Phase 4 | NCT02526823 Comparator | Aug 2015 → Dec 2019 | lymphoma | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT07171827 Background | Mar 2023 → Feb 2025 | classic Hodgkin lymphoma | Helwan University | Completed | No outcome recorded |
| — | NCT03217097 Comparator | Oct 2018 → Jan 2022 | neuroendocrine neoplasm | Hospices Civils de Lyon | Completed | No outcome recorded |
| — | NCT02800447 Comparator | Jun 2016 → Dec 2018 | Hodgkins lymphoma | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| — | NCT02797717 Background | Nov 2015 → Dec 2022 overdue | classic Hodgkin lymphoma | GALIA AVRAHAMI | Recruiting | No outcome recorded |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 229 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dacarbazine | “The "alkylating-based" group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or...” NCT03217097 ↗219“Chemotherapy is based upon regimes with well known effectiveness in Hodgkin lymphoma. (i.e. ABVD: doxorubicin, bleomycin, vinblastine and dacarbazine and ESHAP: Etoposide,...” NCT03500133 ↗ “Patients received trametinib (2 mg orally) once daily or intravenous dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square meter) every 3 weeks.” PMID 22663011 ↗ Jun 2012 “Dacarbazine administered at 1000 mg/m2 by intravenous infusion (IVI), over 90±15 minutes on Day 1 every 21 days until tumor progression or unacceptable toxicity occurs;” NCT02049905 ↗ “A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) Plus Dacarbazine (DTIC) in Chemotherapy Naive Patients With Unresectable Stage III or Stage IV Malignant Melanoma” NCT00327600 ↗ “The other half (Group II) will receive a combination of intravenous Adriamycin, Bleomycin, Vinblastine and Dacarbazine every other week for 12 treatments.” NCT00797472 ↗ “ABVD was given every 28 days (doxorubicin 25 mg/m2, bleomycin 10 mg/m2, vinblastine 6 mg/m2, and dacarbazine 375 mg/m2 intravenously on days 1 and 15)” PMID 30658935 ↗ Jan 2019 “A Randomized, Open-label, Cross-over Pharmacokinetic Study of Dacarbazine in Combination With Genasense® in Subjects With Advanced Melanoma” NCT00542893 ↗ “Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle.” NCT02275598 ↗ “Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)” NCT04307277 ↗ “BACOPP-D regimen which includes cyclophosphamide, adriamycin, dacarbazine, procarbazine, prednisolone, bleomycin and vincristine” NCT00188149 ↗ “Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle” NCT00901303 ↗ “Single-agent or combination chemotherapy regimens include dacarbazine, temozolomide, paclitaxel, and carboplatin.” NCT07406724 ↗ “doxorubicin 25 mg/m\^2 IV bleomycin 10 units/m\^2 IV vinblastine 6 mg/m\^2 IV dacarbazine 375 mg/m\^2 IV” NCT01118026 ↗ “single or combined, including but not limited to dacarbazine, temozolomide, taxoid, or platinum” NCT05868707 ↗ “doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)-based response-adapted therapy” NCT01652261 ↗ “PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma” NCT05466474 ↗ “brentuximab vedotin x 2; doxorubicin x 2; vinblastine x 2; dacarbazine 2x; rituximab x 2” NCT05253495 ↗ “Dacarbazine - 375mg/m2 IV over 30 minutes, Day 1 and 15, every 28 days, 2-6 cycles.” NCT01578967 ↗ “Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule” NCT00795613 ↗ “Gemcitabine i.v. 250 mg/m2 D1 and D8 Dacarbazine i.v. 250 mg/m2 D1 and D8” NCT04535271 ↗ “Dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel.” NCT06264180 ↗ “Dacarbazine injection：375mg/m2，IV infusion，day 1 and 15” NCT02800447 ↗ “AVD (adriamycin,vinblastine sulfate and dacarbazine)” NCT05772624 ↗ “Dacarbazine will be given at 800 mg/m2 IV on day 1” NCT00885534 ↗ “Adriamycin, Bleomycin, Vinblastine and Dacarbazine” NCT00816959 ↗ “Doxorubicin, Vinblastine, and Dacarbazine - AVD” NCT05627115 ↗ “Dacarbazine 375 mg/m2 i.v. day 1 and 15” NCT00433433 ↗ “Dacarbazine 375 mg/m2 i.v. day 1 and 15” NCT00784537 ↗ “Dacarbazine 375 mg/mq i.v. day 1 and 15” NCT01523847 ↗ “Dacarbazine 375 mg/m2 i.v. day 1 and 8” NCT02247869 ↗ “and Dacarbazine, Lomustine, Cisplatin” NCT05898451 ↗ “Cytarabine, Dacarbazine, Dactinomycin” NCT02788201 ↗ “Dacarbazine 375 mg/m2 in D 1 and 15” NCT07234487 ↗ “vinblastine and dacarbazine (ABVD).” NCT00005584 ↗ “Dacarbazine 0.375mg/m2, d1, d15 IV” NCT05900765 ↗ “Dacarbazine：375mg/m2，ivgtt，D1、15；” NCT02526823 ↗ “dacarbazine 375 mg/m2/D” NCT00970385 ↗ “Dacarbazine” NCT01468740 ↗ |
| Known as | Biocarbazine r | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | dacarbacine | “Chemotherapy with dacarbacine (DTIC) is widely accepted as the standard treatment in metastatic melanoma” NCT00779714 ↗ |
| Known as | Dacarbasine | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | Dacarbazina | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | Dacarbazine (DTIC)-Dome | “Dacarbazine (DTIC)-Dome” NCT01133977 ↗ |
| Known as | Dacarbazine - DTIC | “Dacarbazine - DTIC” NCT01835145 ↗ |
| Known as | Dacarbazinum | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | Dacin (Dacarbazin).ATC-Code: L01AX04 | “Dacin (Dacarbazin).ATC-Code: L01AX04” NCT00794235 ↗ |
| Known as | Decarbazine | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | Dicarbazine | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | DTIC | “A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha...” NCT00911443 ↗24“Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.” NCT01055522 ↗ “A Phase 1/2 Trial of Amplimexon® (Imexon, Inj.) Plus Dacarbazine (DTIC) in Chemotherapy Naive Patients With Unresectable Stage III or Stage IV Malignant Melanoma” NCT00327600 ↗ “This is a combination Phase I/II design that explores the toxicity and activity of a combination of sunitinib and Dacarbazine (DTIC) for metastatic melanoma.” NCT00496223 ↗ “Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma” NCT01152788 ↗ “Dacarbazine (DTIC): 375 mg/m\^2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.” NCT03033914 ↗ “Chemotherapy with dacarbacine (DTIC) is widely accepted as the standard treatment in metastatic melanoma” NCT00779714 ↗ “Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients” NCT00553618 ↗ “Dacarbazine (DTIC) has been approved for treating metastatic melanoma in the 1970s” NCT00308607 ↗ “Dacarbazine (DTIC) has been approved for treating metastatic melanoma in the 1970s” NCT00813449 ↗ “Subjects will receive intravenous dacarbazine (DTIC) 1000 mg/m2 every 3 weeks” NCT01227889 ↗ “M200 (volociximab) in Combination with Dacarbazine (DTIC)” NCT00099970 ↗ “Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks” NCT01614301 ↗ “versus dacarbazine (DTIC)” PMID 32610581 ↗ Jun 2020 “dacarbazine or DTIC” NCT00130442 ↗ “Dacarbazine (DTIC)” NCT00504504 ↗ “Dacarbazine (DTIC)” NCT00395070 ↗ “Dacarbazine (DTIC)” NCT04200040 ↗ |
| Known as | DTIC (Dacarbazine) | “DTIC (Dacarbazine)” NCT00597038 ↗ |
| Known as | DTIC-Dome | “DTIC-Dome (Dacarbazine)” NCT00354523 ↗ |
| Known as | NCI C04717 | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Known as | NSC-45388 | ChEMBL registry synonym — accepted as the source's own label CHEMBL476 ↗ |
| Action | Inhibit | “Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine, work in different ways to stop the growth of tumor cells” NCT00654732 ↗ |
| Modality | Small molecule | — CHEMBL476 ↗ |
| Route | Intravenous | “Patients receive doxorubicin, bleomycin, vinblastine, and dacarbazine IV on days 1 and 15 (ABVD).” NCT00002561 ↗ |